By Norris R. McDonald, DIJ, AARC, Respiratory Therapist
SULFABITTAS NEWS, February 28, 2026
In today’s healthcare debate, two realities exist side by side.
On one hand, millions of Americans rely on insurance coverage for cancer treatment, chronic disease management, and preventive care. On the other, compensation packages for top pharmaceutical and medical technology executives have reached tens of millions of dollars annually, largely driven by stock performance and long-term incentive structures.
The contrast is not rhetorical. It is measurable.
Industry reporting from Fierce Biotech shows that Stryker CEO Kevin Lobo received nearly $60 million in total compensation in 2023. Former Sage Therapeutics CEO Barry Greene’s compensation exceeded $58 million in 2021, while former Purdue Pharma CEO Mark Timney was reported at approximately $68 million.
In 2024, BioNTech CEO Uğur Şahin exercised stock options valued at roughly $287 million. In a separate legal case, former pharmaceutical executive Martin Shkreli was ordered to return $64.6 million in profits following price-gouging litigation, according to NPR.
In most cases, such compensation reflects exercised stock options, performance-based incentives, and long-term equity awards rather than direct salary. Corporate boards typically approve these packages within established governance frameworks.
Still, the broader policy context raises important questions.
The Coverage Debate
If the Affordable Care Act (ACA) were repealed or significantly altered without a comprehensive replacement, nonpartisan estimates have suggested that millions of Americans could lose health insurance coverage. Depending on legislative design, some projections have ranged into double-digit millions, with figures as high as 15 million discussed in certain analyses.
Health coverage affects access to cancer screening, early diagnosis, medication adherence, and specialist care. For patients with serious illnesses, even short gaps in coverage can lead to delays in treatment.
 |
| Cancer patients ---even children ---are denied care while BIG Pharma executives make over $60 million in compensation. |
As healthcare policy remains a central political issue, access and affordability continue to dominate public concern.
Innovation, Incentives and Access
Supporters of current compensation models argue that competitive executive pay helps attract experienced leadership capable of guiding complex biomedical companies through research, regulatory approval, and global market expansion. The biotechnology and medtech sectors operate in highly competitive environments, and breakthrough therapies often require significant capital investment and risk.
At the same time, healthcare in the United States remains one of the most expensive systems in the world. High deductibles, out-of-pocket costs, and medical debt remain persistent challenges for many households. Even insured patients sometimes face coverage disputes, prior authorization delays, and shifting formularies.
This tension between innovation incentives and equitable access is not new. It reflects structural questions about how healthcare is financed and governed in a market-based system.
National Spending Priorities
The healthcare discussion also intersects with broader fiscal debates, including defense spending, tax policy, and corporate regulation. Federal budgets reflect political choices about resource allocation, and healthcare remains one of the largest components of national expenditure.
Critics argue that policy reforms have disproportionately benefited high-income earners and corporations, while supporters maintain that such policies stimulate investment and economic growth. The debate is ongoing and highly partisan.
What remains less partisan is the lived experience of patients navigating complex insurance systems while confronting serious illness.
A Question of Balance
The central issue is not whether executive compensation is legal or contractually structured — it typically is. Nor is it whether innovation deserves reward — it does.
The question is whether the healthcare system can balance strong incentives for innovation with broad, stable access to care.
A sustainable healthcare model must support research, encourage investment, and ensure that patients can obtain timely treatment. If millions were to lose coverage during policy transitions, the effects would likely be felt most acutely among individuals with chronic and life-threatening conditions.
As a Respiratory Therapist, I have seen firsthand how continuity of care affects outcomes. Insurance status can influence when patients seek treatment and how consistently they adhere to therapy. Healthcare policy decisions translate directly into clinical realities.
Moving Forward
The United States has the economic capacity to maintain advanced biomedical research while preserving access to essential health services. Achieving both requires careful policy design, fiscal discipline, and public accountability.
Executive compensation, healthcare reform, and insurance coverage are not isolated issues. They are interconnected elements of a broader system that shapes national health outcomes.
As debates over the ACA, corporate governance, and federal spending continue, policymakers face a fundamental responsibility: ensuring that healthcare remains both innovative and accessible.
Because in the end, the strength of a healthcare system is measured not only by shareholder returns — but by patient outcomes.
About the Author
Norris R. McDonald is an author, respiratory therapist, and economic journalist whose work focuses on political economy, public health, healthcare systems, and global public policy. He is a regular contributor of public commentary and analysis for the Jamaica Gleaner, where he examines the intersection of economics, governance, social justice, and development in Jamaica, the Caribbean, and the Global South.
With professional training in respiratory care and decades of frontline healthcare experience, McDonald brings a clinical and evidence-based perspective to issues such as maternal mortality, health inequities, pharmaceutical policy, and healthcare access. His journalism blends data-driven analysis with historical and cultural context, particularly around Black communities, post-colonial development, and structural inequality.
McDonald is also the publisher of Sulfabittas Newsmagazine on Substack, where he produces investigative features, long-form essays, and geopolitical commentary on global power dynamics, economic sovereignty, and emerging multipolar realities.
********************************
BOOKS
Additionally, A Nursing Handbook for New Grads provides a foundational understanding of nursing leadership, patient advocacy, and quality improvement in healthcare. Whether preparing for the NCLEX
.png)
SCAN QR CODE HERE: 👉
GET THE BOOK HERE: 👇
https://www.amazon.com/NURSING-HANDBOOK-NEW-GRADS-excellence/dp/B0DZP5PHNW
.png)
